$1.59
+0.07 (+4.61%)
Open$1.52
Previous Close$1.52
Day High$1.60
Day Low$1.51
52W High$6.18
52W Low$1.07
Volume—
Avg Volume967.5K
Market Cap106.17M
P/E Ratio—
EPS$-0.56
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+2,615.7% upside
Current
$1.59
$1.59
Target
$43.18
$43.18
$31.72
$43.18 avg
$59.84
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 34.78M | 32.14M | 39.05M |
| Net Income | 5.77M | 7.01M | 8.10M |
| Profit Margin | 16.6% | 21.8% | 20.7% |
| EBITDA | 11.08M | 11.55M | 13.91M |
| Free Cash Flow | 4.11M | 3.56M | 7.02M |
| Rev Growth | +3.0% | +6.5% | +17.8% |
| Debt/Equity | 0.16 | 0.15 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |